Indication: Philadelphia Chromosome Ph+ALL
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.
Sub-indication: Philadelphia Chromosome Ph+ALL
Principal Investigator: Ashok Raj, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Children's Oncology Group (COG)